- Home
- ETON vs ALDX Comparison
ETON vs ALDX Comparison
Compare ETON & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ETON | ALDX |
|---|---|---|
| Founded | 2017 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 498.8M | 293.0M |
| IPO Year | 2018 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ETON | ALDX |
|---|---|---|
| Price | $16.94 | $5.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $29.67 | $9.50 |
| AVG Volume (30 Days) | 220.3K | ★ 1.6M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $70,316,000.00 | N/A |
| Revenue This Year | $107.23 | N/A |
| Revenue Next Year | $29.72 | $36.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 102.77 | N/A |
| 52 Week Low | $11.09 | $1.14 |
| 52 Week High | $23.00 | $7.20 |
Technical Indicators
Market Signals| Indicator | ETON | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 53.52 | 51.50 |
| Support Level | $16.53 | $5.04 |
| Resistance Level | $17.33 | $5.75 |
| Average True Range (ATR) | 0.59 | 0.47 |
| MACD | 0.13 | 0.03 |
| Stochastic Oscillator | 74.37 | 67.04 |
Price Performance
Historical ComparisonAbout ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.